Julia Gallwas

Julia Gallwas

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2019 in Molecules
Verified
Journal Article
Open access
PDF file
RLRoland Ladurner
Roland Ladurner
MLMax Lerchenberger
Max Lerchenberger
NANorah Al Arabi
Norah Al Arabi
JGJulia Gallwas
Julia Gallwas
HSHerbert Stepp
Herbert Stepp
KHKlaus Hallfeldt
Klaus Hallfeldt
Injury to parathyroid glands during thyroid and parathyroid surgery is common and postoperative hypoparathyroidism represents a serious complication. Parathyroid glands possess a unique autofluorescence in the near-infrared spectrum which could be used for their identification and protection at an early stage of the operation. In the present study parathyroid autofluorescence was visualized intraoperatively using a standard Storz laparoscopic near-infrared/indocyanine green (NIR/ICG) imaging system with minor modifications to the xenon light source (filtered to emit 690 nm to 790 nm light, less than 1% in the red and green above 470 nm and no blue light). During exposure to NIR light parathyroid tissue was expected to show autofluorescence at 820 nm, captured in the blue channel of the camera. Over a period of 5 years, we investigated 205 parathyroid glands from 117 patients. 179 (87.3%) glands were correctly identified by their autofluorescence. Surrounding structures such as thyroid, lymph nodes, muscle, or adipose tissue did not reveal substantial autofluorescence. We conclude that parathyroid glands can be identified by their unique autofluorescence at an early stage of the operation. This may help to preserve these fragile structures and their vascularization and lower the rate of postoperative hypocalcemia.

15 March 2011 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
JGJulia Gallwas
Julia Gallwas
LTLisa Turk
Lisa Turk
HSHerbert Stepp
Herbert Stepp
SMSusanna Mueller
Susanna Mueller
RORobert Ochsenkuehn
Robert Ochsenkuehn
CDChristian Dannecker
Christian Dannecker

15 April 2010 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PDF file
JGJulia Gallwas
Julia Gallwas
LTL. Turk
L. Turk
KFK. Friese
K. Friese
CDC. Dannecker
C. Dannecker

19 November 2013 in Lasers in Surgery and Medicine
Verified
Journal Article
Closed access
PDF file
RLRoland Ladurner
Roland Ladurner
KHKlaus K.J. Hallfeldt
Klaus K.J. Hallfeldt
NANorah Al Arabi
Norah Al Arabi
HSHerbert Stepp
Herbert Stepp
SMSusanna Mueller
Susanna Mueller
JGJulia Gallwas
Julia Gallwas

23 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
MLMatthias Laesche
Matthias Laesche
HUHorst Urban
Horst Urban
JGJulia Gallwas
Julia Gallwas
Carsten GründkerCarsten Gründker
Carsten Gründker
Cervical cancer is responsible for around 5% of all human cancers worldwide. It develops almost exclusively from an unsolved, persistent infection of the squamocolumnar transformation zone between the endo- and ecto-cervix with various high-risk (HR) human papillomaviruses (HPVs). The decisive turning point on the way to persistent HPV infection and malignant transformation is an immune system weakened by pathobionts and oxidative stress and an injury to the cervical mucosa, often caused by sexual activities. Through these injury and healing processes, HPV viruses, hijacking activated keratinocytes, move into the basal layers of the cervical epithelium and then continue their development towards the distal prickle cell layer (Stratum spinosum). The microbial microenvironment of the cervical tissue determines the tissue homeostasis and the integrity of the protective mucous layer through the maintenance of a healthy immune and metabolic signalling. Pathological microorganisms and the resulting dysbiosis disturb this signalling. Thus, pathological inflammatory reactions occur, which manifest the HPV infection. About 90% of all women contract an HPV infection in the course of their lives. In about 10% of cases, the virus persists and cervical intra-epithelial neoplasia (CIN) develops. Approximately 1% of women with a high-risk HPV infection incur a cervical carcinoma after 10 to 20 years. In this non-systematic review article, we summarise how the sexually and microbial mediated pathogenesis of the cervix proceeds through aberrant immune and metabolism signalling via CIN to cervical carcinoma. We show how both the virus and the cancer benefit from the same changes in the immune and metabolic environment.

16 April 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ASAnna Semmlinger
Anna Semmlinger
VSViktoria von Schoenfeldt
Viktoria von Schoenfeldt
VWVerena Wolf
Verena Wolf
AMAlexandra Meuter
Alexandra Meuter
TKTheresa Maria Kolben
Theresa Maria Kolben
NDNina Ditsch
Nina Ditsch
In various cancers, overexpression of cyclooxygenase (COX)-2 and elevated prostaglandin (PG) E2 synthesis have been associated with tumor development and progression. The potential of COX-2 inhibitors in cancer prevention and treatment has been shown repeatedly; however, their clinical use is limited due to toxicity. PGE2 signals via EP receptors 1–4, whose functions are analyzed in current research in search for targeted anti-PG therapies. EP2 and EP4 rather promote tumorigenesis, while the role of EP3, especially in breast cancer, is not yet clear and both pro- and anti-tumorigenic effects have been described. Our study evaluates EP3 receptor expression in sporadic breast cancer and its association with clinicopathological parameters, progression-free and overall survival. Two hundred eighty-nine sporadic breast cancer samples without primary distant metastasis were immunohistochemically analyzed for EP3 receptor expression. Tissue was stained with primary anti-EP3-antibodies. Immunoreactivity was quantified by the immunoreactivity-score (IRS); samples with an IRS ≥ 2 scored as EP3 positive. Chi-squared and Mann-Whitney-U test were used for comparison of data; Kaplan-Meier estimates and Cox-regression were used for survival analyses. EP3 receptor was expressed in 205 of 289 samples analyzed (70.9%). EP3 receptor expression was not associated with clinicopathological parameters (e. g. tumor size, hormone receptors, lymph node status). Kaplan-Meier estimates showed a significant association of EP3 positivity with improved progression-free survival (p = 0.002) and improved overall survival (p = 0.001) after up to 10 years. Cox regression analysis confirmed EP3 positivity as a significant prognostic factor even when other known prognosticators were accounted for. In sporadic breast cancer, EP3 receptor expression is not significantly associated with clinicopathological parameters but is a significant prognostic factor for improved progression-free and overall survival. However, the functional aspects of EP3 receptor in breast cancer and the way how EP3 may oppose the pro-tumorigenic effects of PGE2 elevation and COX-2 overexpression are not fully understood so far. Further studies aiming at identification of the factors regulated by EP3 are necessary to evaluate the possibility of targeting EP3 in future anti-tumor therapy in breast cancer.